tested for allelic loss. Seven of nine tumors constitutionally heterozygous for chromosome 4q markers showed allele loss in tumor tissue. Six of the seven samples were jointly informative for both 4p and 4q markers. Five of the six demonstrated loss for only 4q RFLPs. In one individual, in which two samples were taken from distant locations within the same tumor, both samples showed loss of the same alleles. Among the other chromosomes informative for allele loss, one tumor showed changes on 13q. No other changes were observed in RFLPs located on the eight other chromosomes tested. These results indicate that an anti-oncogene may be located on 4q and suggest a mechanism for PHC and other cancers seroepidemiologically related to virus infection. Liver cancer caused by chronic HBV infection or other environmental agents may be linked through genetic events responsible for the loss of a tumor suppressor locus (anti-oncogene) located on chromosome 4.
Primary hepatocellular carcinoma (PHC) is the third most common cause of cancer mortality worldwide, accounting for 250,000-1,000,000 deaths annually (1). Epidemiologic studies have firmly established chronic hepatitis B virus (HBV) infection as an important risk factor for PHC (2-4). Little, however, is known about the oncogenic mechanism. To date, the specific genetic event(s) responsible for transformation in PHC has not been established (5, 6) . The role of virally mediated oncogenesis has been extensively explored. As yet, no conclusive results have emerged (see refs. 5 and 6 for reviews). Nonvirally mediated dominant oncogenesis has also been evaluated in PHC. Studies in woodchucks (Marmota monax), an animal model for PHC, have shown that three of nine PHC tumors have enhanced expression of a rearranged c-myc protooncogene (human chromosome 8) (7) . No similar results have been reported in human PHC. Transforming sequences from human PHC have not been reproducibly isolated.
Alternatively, a recessive etiology (8) similar to that observed in a variety of cancers may be involved in PHC oncogenesis. Many solid tumors have been shown to demonstrate genetic changes (loss of constitutional heterozygosity) consistent with a recessive oncogenic mechanism (9) (10) (11) (12) (13) . A somatic cell hybrid study in an experimental system has provided preliminary evidence that PHC may have a recessive etiology. Hybrids between a cell line derived from a spontaneous mouse hepatoma and normal rat embryo skin fibroblasts do not express a transformed phenotype (14) . A suppressing locus (loci) has been localized to rat chromosome 8 based on the evidence that the suppressed hybrid subclones that reexpress a transforming phenotype have lost that chromosome (15) . The human analogs for rat chromosome 8 are largely unknown. Preliminary studies in humans provide further evidence for a recessive etiology for PHC. Loss of constitutional heterozygosity in PHC has been reported for loci on chromosomes 4q, 11p, and 13q (16, 17) .
MATERIALS AND METHODS
Sample Population. For the purpose of characterizing the genetic constitution of human PHCs, we have tested a collection of probes to anonymous and candidate loci distributed throughout the human genome on a collection of 12 pairs of tumor and nontumor tissue. Samples were obtained from three sources: the Liver Research and Education Foundation (LREF) ofthe Rancho Los Amigos Hospital, Downey, CA (five tumors); the University of California-Irvine (UCI) (four tumors), and the Liver Cancer Prevention Center (LCPC) of the Fox Chase Cancer Center, Philadelphia (three tumors). The samples were obtained from an ethnically heterogeneous group of patients. The collection includes samples from four South African Blacks (UCI1-4), one American Black (LREF2), three European Caucasians (LREF1, LREF5, LCPC1), one Thai (LREF4), one Tonganese (LREF3), one Japanese (LCPC2), and one Vietnamese (LCPC3). All but one of the tumors in the collection could be shown to be HBV associated. One tumor, for which no serological data were available, did not contain integrated HBV sequences in the tumor DNA (UCI1). All remaining tumors contained integrated HBV sequences.
Restriction Fragment Length Polymorphism (RFLP) Analysis. For each patient, samples of both tumor and nontumor material were obtained. Nontumor material consisted of either uninvolved liver tissue or peripheral lymphocytes.
DNA extraction and RFLP screening in both normal and tumor samples were carried out by standard methods (18) . DNA was extracted from whole blood and liver tissue by a Abbreviations: PHC, primary hepatocellular carcinoma; HBV, hepatitis B virus; RFLP, restriction fragment length polymorphism. iTo whom reprint requests should be addressed.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. modification of the procedure of Poncz et al. (19) . After DNA extraction, normal and tumor samples from each individual were digested with restriction enzymes and electrophoresed on 0.8-1.2% agarose gels. The DNA was then transferred to Zetabind filters (AMF Cuno) using 0.4 M NaOH. The filters were prehybridized, hybridized, and washed according to the manufacturer's instructions. DNA probes were labeled by the random primer method of Feinberg and Vogelstein (20) and the blots were autoradiographed using intensifying screens. The probes as well as their chromosomal location and polymorphic restriction digests tested are presented in Table 1 ( .
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RESULTS
The results of typing probes localized to chromosomes 1 (renin), 2 [D2S44, transforming growth factor a (TGFA)], 4 [D4S125, serum albumin (ALB)], 6 [serum plasminogen (PLG)], 7 [epidermal growth factor receptor (EGF-R)], 11p
[n3-hemoglobin (HBG), and H-RAS], 13q (D13S11, D13S12), 14 (D14S15), and 17 (D17S4) are summarized in Fig. 1 . One of the seven sample sets informative (heterozygous in uninvolved tissue) for the chromosome 13q probes showed loss of an allele in the tumor tissue (LCPC3). Five offive informative samples showed loss of an allele for ALB at 4q11-q12 in tumors. Four of the five samples that showed allele loss for ALB were jointly informative for pYNZ32 on 4pl6. None of these tumors showed allele loss for the short arm marker. No tumors showed loss of alleles or aberrant restriction digestion patterns for loci on chromosomes 1 (0 of 8), 2 (0 of 7), 6 (0 of 2), 7 (0 of 4), 11p (0 of 6), 14 (0 of 2), or 17 (0 of 5). It is possible to determine the significance of the above rates by comparing them with the loss rate observed in other tumors of known recessive etiology. Studies of syntenic RFLPs in the recessive paradigm, retinoblastoma (9, 10) , indicate that a loss rate of =50% may be expected. It is currently not feasible in PHC to estimate an expected background (noncausal) genome alteration rate related to tumor progression and/or viral disruption. At present, no cytogenetic data are available from nonpassaged PHC tumors.
However, cytogenetic studies of a variety of other carcinomas show that individual chromosomes display aberrations in -23% of tumors studied (56) . Aberrations were defined as change in observed number or structure of a given chromosome and did not reflect changes in ploidy (which would not affect heterozygosity analysis). Therefore, 23% reflects a noncausative (background) loss rate, which may be expected by chance.
Using standard statistical methods, the background and causal change rates can be used to estimate the probability of the observed frequencies of loss and no loss of alleles in tumors. Presented in Fig. 1 50% loss rate. However, after adjusting the rejection criterion for the fact that 10 different chromosomes were tested (a = 0.005), only chromosome lq's observed loss rate was significantly lower than the postulated causal rate. Therefore, chromosome iq could be judged as uninvolved or excluded from further screening based on statistical criteria. Conversely, the probability of the observed loss rates could be determined assuming the 23% background rate. The 1 of 7 loss observed for chromosome 13q was not significantly different from the background rate (the probability of 1 or loss given a 23% rate = 0.84). The chromosome 4q results, however, were significantly different from the 23% rate (P < 0.0001), even after adjustment for multiple tests. Eleven additional loci mapped to chromosome 4 (refs. 21 and 57; K.H. and J.C., unpublished results) were typed on the sample material in an attempt to increase the number of informative cases and to localize the region of change (see Fig. 2 ). Two additional tumors were found to demonstrate loss of heterozygosity for chromosome 4 (bringing the total showing loss to 7 of 12). Six of the 7 cases showing chromosome 4 allele loss were jointly informative for one or more markers assigned to the short and long arms. Sample LREF1 showed loss of alleles for both short and long arm markers. Five of the 6 tumors showed loss ofalleles only for the 4q loci, thereby localizing the proposed tumor suppressor locus to the long arm. Seven of the 12 cases were informative for a marker (D4S67) localized to the centromeric region of chromosome 4. No loss was observed for any of the informative cases. One sample set, LREF5, had two tumor samples drawn from physically distant localizations. Both samples showed identical loss patterns. An illustration of the chromosome 4 screening is presented in Fig. 3 .
Two previous studies have reported loss of heterozygosity in PHC. The first report (16) observed that 3 of 4 PHC tumors showed allele loss at the EGF locus on chromosome 4q. Tests of chromosomal specificity showed that RFLPs on three other chromosomes (nos. 1, 7, and 9) showed no change in tumor tissue. A second study (17) reported that 1 in 5 tumors informative for a marker locus on 4p demonstrated allele loss. In addition, 6 of 14 tumors showed loss of constitutional heterozygosity for chromosomes 11p, 5 of 10 tumors showed allele loss for 13q, 1 in 3 showed allele loss for 10, and 2 of 10 showed allele loss in tumor tissue for chromosome 17. No changes were observed for RFLPs on chromosomes lq, 2p, 3q, 5, 7q, 9q, 12p, 14q, 15q, 19, 20, 21q, or 22q.
Combining the current study's results with those obtained from the others, it was observed that 6 of 20 tumors showed allele loss for 11p, 6 of 17 showed allele loss for 13q, and 10 of 13 showed loss for 4q. The chromosome 10q, 11p, 13q, and 17q allele loss rates are not significantly different from the background rate. The probability of observing this many allele loss events and more, assuming a random loss frequency of 23%, is 0.54 for 10q, 0.30 for 11p, 0.18 for 13q, and 0.71 for 17q. Conversely, the chromosome 10q, 11p, 13q , and 17q loss rates will be observed with probabilities 0.50, 0.06, 0.17, and 0.05, respectively, when the expected loss frequency is 50%. The chromosome 4q results are significantly different from the background rate (P < 0.0001) and suggest a causal rate of 50% or greater.
Pasquinelli et al. (46) have cloned a host sequence (HVBS6) adjacent to an HBV integration site mapped by in situ hybridization to 4q32. They observed this sequence to be disrupted in 3 of 40 PHCs. The current sample collection was screened with HVBS6 to determine whether alterations at this locus could be involved with the 4q loss of heterozygosity observed in the tumor samples. Uninvolved and PHC tissue sample pairs digested with five different restriction enzymes (HindIII, Pst I, Rsa I, Sac I, and Taq I) were probed with HVBS6. No fragments were observed in tumor tissue that were not present in the uninvolved tissue typed. It is not unlikely, however, that the low frequency of changes previously observed would be missed given the relatively small sample size of the current study (P = 0.39). Two samples (LCP2 and UCI4) constitutionally heterozygous for HVBS6 RFLPs were observed to show allele loss in tumors.
Information on the HBV integration pattern was also available from the tumor samples. A variable number of tandem repeat (VNTR) sequences (28) have been speculated to be preferential HBV integration sites (58) . Five VNTR class probes, three of which were derived from HBV sequences (D2S44, D14S15, and D17S4), were used in the screening panel. Two of the VNTRs, D4S125 and D4S95, were located on the short arm of chromosome 4. No evidence of alteration of restriction digest pattern detectable by standard Southern blot analysis was observed in any of the tumors tested. This suggests that neither were large segments Southern blot results for tI probes spanning the length of chromosc polymorphic bands for each RFLP detec is observed to be heterozygous in nont epidermal growth factor, and P-fibrinogc in tumor tissue (t) for any of the chror demonstrates heterozygosity for the mat interferon-induced protein (IP10). Only shows allele loss. LREF1 shows constil for D4S98, IP10, epidermal growth factor probes detect allele loss in tumor tissue of HBV integrated nor did integrati( ments occur at these locations in th
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